The Central Precocious Puberty Market is estimated to be valued at US$ 1.722.2 Mn or Million in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Central precocious puberty refers to the early development of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys. The major causes of central precocious puberty include genetic mutations, brain tumors, brain injuries and neurocutaneous syndromes. The key treatment options available in the market include gonadotropin-releasing hormone analogs such as leuprolide and histrelin. These drugs help suppress the release of sex hormones from the ovaries and testes to delay puberty.
Market Dynamics:
One of the major drivers fueling growth of the central precocious puberty market is the increasing prevalence of the disorder globally. According to a report by the European Society for Paediatric Endocrinology, the prevalence of central precocious puberty is estimated to be around 1 in 5,000 to 1 in 10,000 children. Moreover, rising awareness regarding the availability of effective treatment options is also augmenting demand for hormonal therapies. For instance, leuprolide acetate is an established first line treatment for central precocious puberty. However, high cost of hormonal drugs is a major factor restraining growth of this market. Additionally, lack of diagnosis in developing regions also poses a challenge.
Here is the content in 700 words for the given inputs:
Segment Analysis
Content: The central precocious puberty market is dominated by gonadotropin-releasing hormone agonists sub segment. This sub segment accounts for over 80% of total central precocious puberty market share owing to factors such as high efficacy, longer treatment duration of 3 years as compared to other therapies requiring daily administration, and reduced painful injections as compared to other therapies.
PEST Analysis
Political: Regulatory bodies such as FDA scrutinize the drug manufacturing process and approval process for any new drug entities entering this market which ensures patient safety.
Economic: The rising personal disposable incomes in developed regions and increasing health awareness is driving high spending on pediatric healthcare and specialty drugs for conditions like central precocious puberty.
Social: Growing social support systems for conditions like central precocious puberty and increasing patient advocacy is creating more awareness regarding the available treatment options for children with central precocious puberty.
Technological: Advancements in drug delivery systems help reduce injection frequency and related side effects for patients undergoing central precocious puberty therapies.
Key Takeaways
The global Market is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period of 2028 to 2030, due to increasing awareness regarding the condition and availability of branded drugs. The market was valued at US$ 1.722.2 Mn in 2023.
Regional analysis: North America is expected to dominate the central precocious puberty market owing to factors such as early adoption of advanced treatment therapies, presence of major market players, and high disposable incomes supporting high healthcare spending. The Asia Pacific region is anticipated to exhibit the fastest growth in the central precocious puberty market during the forecast period due to large patient pool and rising medical tourism.
Key players operating in the Central Precocious Puberty market are Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited. Key players are focused on new drug approvals and launches to strengthen their market position. For instance, Teva Pharmaceuticals received FDA approval for oral eltrombopag for treatment of immune thrombocytopenia in 2021.